HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model-Reference-Cited by-同舟云学术

HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model

Published:2020-06 Issue: Volume:144 Page:20-29
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Stockhammer Paul,Ho Cassandra Su Lyn,Hegedus Luca,Lotz Gabor,Molnár Eszter,Bankfalvi Agnes,Herold Thomas,Kalbourtzis Stavros,Ploenes Till,Eberhardt Wilfried E.E.,Schuler Martin,Aigner Clemens,Schramm Alexander,Hegedus Balazs

Funder

Semmelweis University Start-Up Grant

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference55 articles.

1. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer;Katayama;Cancer Sci.,2018

2. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N. Engl. J. Med.,2010

3. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N. Engl. J. Med.,2013

4. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

5. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer;Noh;J. Pathol.,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in dual-targeting inhibitors of HDAC6 for cancer treatment;European Journal of Medicinal Chemistry;2024-09

2. Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer;Journal of Enzyme Inhibition and Medicinal Chemistry;2024-03-11

3. Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma;Lung Cancer;2023-11

4. Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK- LIMS1 Fusion: A Case Report;OncoTargets and Therapy;2023-02

5. Histone deacetylases modulate resistance to the therapy in lung cancer;Frontiers in Genetics;2022-10-03